HOME >> BIOLOGY >> NEWS
Experimental hantavirus vaccine elicits strong antibody response in primates

For the first time, scientists have demonstrated that an experimental vaccine to hantavirus pulmonary syndrome (HPS), a highly lethal disease, elicits a strong neutralizing antibody response in laboratory animals--a response that is key to preventing the virus from causing infection.

In addition, the antibodies, produced in nonhuman primates that received the vaccine, protected hamsters from disease even when administered 5 days after exposure.

These findings provide proof of concept in nonhuman primates for a vaccine against HPS, as well as for post exposure prophylactic treatment of HPS and a related disease known as hemorrhagic fever with renal syndrome (HFRS).

In an article published in last month's Journal of Virology, investigators at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) describe using a naked DNA approach to develop a hantavirus vaccine. The technique involves vaccination with plasmid DNA that encodes a specific hantavirus gene. When the plasmid DNA is introduced into the cells of a vaccine recipient, using a harmless device called a "gene gun," the cloned gene is expressed and presented to the immune system.

According to senior author Jay W. Hooper, Ph.D., the USAMRIID team constructed an expression plasmid containing the full-length M genome segment of Andes virus, a South American hantavirus. Vaccination with the plasmid elicited a potent neutralizing antibody response in rhesus macaques that were vaccinated a total of four times at three-week intervals.

To look at the duration of that response, the team collected serum samples for about six months. The monkeys who received the Andes vaccine displayed robust antibody levels as long as 25 weeks after the last vaccination.

Hantaviruses are carried by rodents and have caused epidemics in Europe, Asia, and the Americas. Some cause HPS, while others are responsible for the more common HFRS. The viruses are patho
'"/>

Contact: Caree Vander Linden
Caree.Vander-Linden@amedd.army.mil
301-619-2285
US Army Medical Research Institute of Infectious Diseases
23-Oct-2003


Page: 1 2 3

Related biology news :

1. Experimental drug shown to block mutant protein causing blood disease
2. Experimental smallpox DNA vaccine protects primates from lethal monkeypox
3. Experimental smallpox vaccine protects against monkeypox in nonhuman primates
4. Experimental Biology 2004 - Translating the Genome
5. Experimental Biology 2004 meets in Washington, D.C. April 17-21
6. Experimental cancer drugs may halt events that lead to cardiac hypertrophy and heart failure
7. Experimental Biology 2003 meets in San Diego April 11-15
8. Experimental Biology 2003 meets in San Diego April 11-15
9. Experimental gene switch increases lifespan with no ill effects
10. Experimental therapy stops allergic reactions in mice
11. APS awards 44 minority travel fellowships to the Experimental Biology 2002 meeting

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/11/2017)... Research and Markets has announced the addition of the "Global ... ... at a CAGR of 30.37% during the period 2017-2021. ... based on an in-depth market analysis with inputs from industry experts. ... the coming years. The report also includes a discussion of the ...
(Date:4/6/2017)... Forecasts by Product Type (EAC), ... End-Use (Transportation & Logistics, Government & Public Sector, Utilities ... Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), ... you looking for a definitive report on the $27.9bn ... ...
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... to expand at a CAGR of 25.76% during the ... is the primary factor for the growth of the ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem ... technology, application, and geography. The stem cell market of ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... LINDA, CA (PRWEB) , ... October 11, 2017 ... ... to upregulate any gene in its endogenous context, enabling overexpression experiments and avoiding ... (CRISPRa) system with small RNA guides is transformative for performing systematic gain-of-function studies. ...
(Date:10/11/2017)... HILLS, Calif. , Oct. 11, 2017  SkylineDx today ... (ICR) and University of Leeds ... risk-stratify patients with multiple myeloma (MM), in a multi-centric Phase ... University of Leeds is the sponsor ... and ICR will perform the testing services to include high-risk ...
(Date:10/10/2017)... Angeles, CA (PRWEB) , ... ... ... Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, ... uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in ...
(Date:10/10/2017)... ... October 10, 2017 , ... USDM Life Sciences , ... life sciences and healthcare industries, announces a presentation by Subbu Viswanathan and Jennifer ... “Automating GxP Validation for Agile Cloud Platforms,” will present a revolutionary approach to ...
Breaking Biology Technology:
Cached News: